5-chloro-4,6-dimethylisoxazolo[5,4-b]pyridin-3-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异恶唑并吡啶类
• 英文名称: 5-chloro-4,6-dimethylisoxazolo[5,4-b]pyridin-3-amine
• 英文别名: 5-chloro-4,6-dimethyl-[1,2]oxazolo[5,4-b]pyridin-3-amine
• 化学式: C₈H₈ClN₃O
• mdl: MFCD07658596
• 分子量: 197.624
• InChiKey: XEYWCHKONZUDGB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  64.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-chloro-4,6-dimethylisoxazolo[5,4-b]pyridin-3-amine 、 氯甲酸苯酯 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 以71%的产率得到phenyl (5-chloro-4,6-dimethylisoxazolo[5,4-b]pyridin-3-yl)carbamate
  参考文献：
  名称：

  [EN] INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 AND TDO) AND THEIR USE IN THERAPY
  [FR] INHIBITEURS DES TRYPTOPHANE-DIOXYGÉNASES (IDO1 ET TDO) ET LEUR UTILISATION EN THÉRAPIE

  摘要：

  本文描述了含有式I中具有IDO1和/或TDO抑制活性的3-氨基异噁唑吡啶化合物的制药组合物，其中W为CR1、N或N-氧化物；X为CR2、N或N-氧化物；Y为CR3、N或N-氧化物；Z为CR4、N或N-氧化物；并且W、X、Y和Z中至少有一个为N或N-氧化物；R9和R10如所定义。还描述了使用这种化合物治疗各种疾病（如癌症）的方法。

  公开号：

  WO2017034420A1
• 作为产物：
  描述：

  2,5-二氯-4,6-二甲基烟腈 在 乙酰氧肟酸 、 potassium tert-butylate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 7.0h， 以45%的产率得到5-chloro-4,6-dimethylisoxazolo[5,4-b]pyridin-3-amine
  参考文献：
  名称：

  [EN] INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 AND TDO) AND THEIR USE IN THERAPY
  [FR] INHIBITEURS DES TRYPTOPHANE-DIOXYGÉNASES (IDO1 ET TDO) ET LEUR UTILISATION EN THÉRAPIE

  摘要：

  本文描述了含有式I中具有IDO1和/或TDO抑制活性的3-氨基异噁唑吡啶化合物的制药组合物，其中W为CR1、N或N-氧化物；X为CR2、N或N-氧化物；Y为CR3、N或N-氧化物；Z为CR4、N或N-氧化物；并且W、X、Y和Z中至少有一个为N或N-氧化物；R9和R10如所定义。还描述了使用这种化合物治疗各种疾病（如癌症）的方法。

  公开号：

  WO2017034420A1

文献信息

• [EN] INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 AND TDO) AND THEIR USE IN THERAPY<br/>[FR] INHIBITEURS DE TRYPTOPHANE DIOXYGÉNASES (IDO1 ET TDO) ET LEUR UTILISATION EN THÉRAPIE
  申请人：AUCKLAND UNISERVICES LTD

  公开号：WO2016024233A1

  公开（公告）日：2016-02-18

  Pharmaceutical compositions comprising 3-aminoisoxazolopyridine compounds of the Formula I having IDO1 and/or TDO inhibitory activity are described, where W is CR1, N or N-oxide; X is CR2, N or N-oxide; Y is CR3, N or N-oxide; Z is CR4, N or N-oxide; and at least one of W, X, Y, and Z is N or N-oxide; and R9 and R10 are as defined. Also described are methods of using such compounds in the treatment of various conditions, such as cancer.

  描述了包含具有IDO1和/or TDO抑制活性的3-氨基异恶唑啉化合物I的药物组合物，其中W是CR1，N或N-氧化物；X是CR2，N或N-氧化物；Y是CR3，N或N-氧化物；Z是CR4，N或N-氧化物；W、X、Y和Z中的至少一个是N或N-氧化物；R9和R10如所定义。还描述了使用这些化合物治疗各种疾病，如癌症的方法。
• Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy
  申请人：AUCKLAND UNISERVICES LIMITED

  公开号：US10888567B2

  公开（公告）日：2021-01-12

  Pharmaceutical compositions comprising 3-aminoisoxazolopyridine compounds of the Formula I having IDO1 and/or TDO inhibitory activity are described, where W is CR1, N or N-oxide; X is CR2, N or N-oxide; Y is CR3, N or N-oxide; Z is CR4, N or N-oxide; and at least one of W, X, Y, and Z is N or N-oxide; and R9 and R10 are as defined. Also described are methods of using such compounds in the treatment of various conditions, such as cancer.

  描述了包含具有 IDO1 和/或 TDO 抑制活性的式 I 的 3-氨基异噁唑吡啶化合物的药物组合物，其中 W 是 CR1、N 或 N-氧化物；X 是 CR2、N 或 N-氧化物；Y 是 CR3、N 或 N-氧化物；Z 是 CR4、N 或 N-氧化物；W、X、Y 和 Z 中至少有一个是 N 或 N-氧化物；R9 和 R10 如所定义。 还描述了使用此类化合物治疗各种疾病（如癌症）的方法。
• INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 AND TDO) AND THEIR USE IN THERAPY
  申请人：Auckland Uniservices Limited

  公开号：EP3180002A1

  公开（公告）日：2017-06-21
• INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 and TDO) AND THEIR USE IN THERAPY
  申请人：Palmer Brian Desmond

  公开号：US20170224701A1

  公开（公告）日：2017-08-10

  Pharmaceutical compositions comprising 3-aminoisoxazolopyridine compounds of the Formula I having IDO1 and/or TDO inhibitory activity are described, where W is CR 1 , N or N-oxide; X is CR 2 , N or N-oxide; Y is CR 3 , N or N-oxide; Z is CR 4 , N or N-oxide; and at least one of W, X, Y, and Z is N or N-oxide; and R 9 and R 10 are as defined. Also described are methods of using such compounds in the treatment of various conditions, such as cancer.
• Inhibitors of Tryptophan Dioxygenases (IDO1 and TDO) And Their Use In Therapy
  申请人：Auckland UniServices Limited

  公开号：US20180244692A1

  公开（公告）日：2018-08-30

  Pharmaceutical compositions comprising 3-aminoisoxazolopyridine compounds of the Formula I having IDO1 and/or TDO inhibitory activity are described, where W is CR1, N or N-oxide; X is CR2, N or N-oxide; Y is CR3, N or N-oxide; Z is CR4, N or N-oxide; and at least one of W, X, Y, and Z is N or N-oxide; and R9 and R10 are as defined. Also described are methods of using such compounds in the treatment of various conditions, such as cancer.